Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Bit.bio has lift­ed the cur­tain on its ear­ly pipeline of re­gen­er­a­tive med­i­cine can­di­dates made us­ing its cell pro­gram­ming tech­nol­o­gy, which is in­tend­ed to de­ter­min­is­ti­cal­ly trans­form stem cells in­to ma­ture cells.

The UK-based com­pa­ny’s lead cell ther­a­py pro­gram, bb­HEP01, com­pris­es en­cap­su­lat­ed he­pa­to­cyte-like cells made us­ing its op­ti-ox tech­nol­o­gy. Bit.bio had pre­vi­ous­ly ex­pressed am­bi­tions to move in­to cell ther­a­py R&D us­ing op­ti-ox but had not un­veiled the specifics of its pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER